Age-related macular degeneration: Advances in management and diagnosis

Journal of Clinical Medicine

Volumn 4, Issue 2, 2015, Pages 343-359

  Yonekawa, Yoshihiro ^a   Miller, Joan W ^a   Kim, Ivana K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Fluorescein angiography; Fundus autofluorescence; Optical coherence tomography; Retina; Vascular endothelial growth factor; Visual impairment

Indexed keywords

AFLIBERCEPT; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BEVACIZUMAB; LAMPALIZUMAB; OMEGA 3 FATTY ACID; PEGAPTANIB; PHOTOSENSITIZING AGENT; RANIBIZUMAB; VASCULOTROPIN; VERTEPORFIN; ZINC;

AGE; AGE RELATED MACULAR DEGENERATION; CAUCASIAN; CLINICAL FEATURE; COMORBIDITY; FLUORESCENCE ANGIOGRAPHY; GENDER; GEOGRAPHIC ATROPHY; HISTOPATHOLOGY; HUMAN; LASER COAGULATION; MACULAR DEGENERATION; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SMOKING; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 84952637408     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4020343     Document Type: Review

References (96)

1. Miller, J.W. Age-related macular degeneration revisited—Piecing the puzzle: The LXIX Edward jackson memorial lecture. Am. J. Ophthalmol.2013, 155, doi:10.1016/j.ajo.2012.10.018.
2. Friedman, D.S.; O’Colmain, B.J.; Munoz, B.; Tomany, S.C.; McCarty, C.; de Jong, P.T.; Nemesure, B.; Mitchell, P.; Kempen, J. Prevalence of age-related macular degeneration in the united states. Arch. Ophthalmol. 2004, 122, 564–572.
3. WHO. Prevention of Blindness and Visual Impairment; Priority Eye Diseases. Available online: http://www.who.int/blindness/causes/priority/en/index8.html (accessed on 30 June 2014).
4. Ferris, F.L., III; Fine, S.L.; Hyman, L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol. 1984, 102, 1640–1642.
5. Klein, R.; Rowland, M.L.; Harris, M.I. Racial/ethnic differences in age-related maculopathy. Third national health and nutrition examination survey. Ophthalmology1995, 102, 371–381.
6. Klein, R.; Chou, C.F.; Klein, B.E.; Zhang, X.; Meuer, S.M.; Saaddine, J.B. Prevalence of age-related macular degeneration in the us population. Arch. Ophthalmol. 2011, 129, 75–80.
7. AREDS-Study-Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-related eye disease study report number 3. Ophthalmology2000, 107, 2224–2232.
8. Klein, R.; Klein, B.E.; Jensen, S.C.; Meuer, S.M. The five-year incidence and progression of age-related maculopathy: The beaver dam eye study. Ophthalmology1997, 104, 7–21.
9. Mitchell, P.; Smith, W.; Attebo, K.; Wang, J.J. Prevalence of age-related maculopathy in australia. The blue mountains eye study. Ophthalmology1995, 102, 1450–1460.
10. Klein, R.; Klein, B.E.; Linton, K.L. Prevalence of age-related maculopathy. The beaver dam eye study. Ophthalmology1992, 99, 933–943.
11. Leibowitz, H.M.; Krueger, D.E.; Maunder, L.R.; Milton, R.C.; Kini, M.M.; Kahn, H.A.; Nickerson, R.J.; Pool, J.; Colton, T.L.; Ganley, J.P.; et al. The framingham eye study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975. Surv. Ophthalmol. 1980, 24, 335–610.
12. Vingerling, J.R.; Dielemans, I.; Hofman, A.; Grobbee, D.E.; Hijmering, M.; Kramer, C.F.; de Jong, P.T. The prevalence of age-related maculopathy in the rotterdam study. Ophthalmology1995, 102, 205–210.
13. Fraser-Bell, S.; Donofrio, J.; Wu, J.; Klein, R.; Azen, S.P.; Varma, R. Sociodemographic factors and age-related macular degeneration in latinos: The los angeles latino eye study. Am. J. Ophthalmol. 2005, 139, 30–38.
14. Sommer, A.; Tielsch, J.M.; Katz, J.; Quigley, H.A.; Gottsch, J.D.; Javitt, J.C.; Martone, J.F.; Royall, R.M.; Witt, K.A.; Ezrine, S. Racial differences in the cause-specific prevalence of blindness in east baltimore. N. Engl. J. Med. 1991, 325, 1412–1417.
15. Christen, W.G.; Glynn, R.J.; Manson, J.E.; Ajani, U.A.; Buring, J.E. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA1996, 276, 1147–1151.
16. Seddon, J.M.; Willett, W.C.; Speizer, F.E.; Hankinson, S.E. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA1996, 276, 1141–1146.
17. Sperduto, R.D.; Hiller, R. Systemic hypertension and age-related maculopathy in the Framingham Study. Arch. Ophthalmol. 1986, 104, 216–219.
18. Goldberg, J.; Flowerdew, G.; Smith, E.; Brody, J.A.; Tso, M.O. Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey. Am. J. Epidemiol. 1988, 128, 700–710.
19. Hyman, L.; Schachat, A.P.; He, Q.; Leske, M.C. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch. Ophthalmol. 2000, 188, 351–358.
20. Klein, R.; Klein, B.E.; Tomany, S.C.; Cruickshanks, K.J. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology2003, 110, 1273–1280.
21. Van Leeuwen, R.; Ikram, M.K.; Vingerling, J.R.; Witteman, J.C.; Hofman, A.; de Jong, P.T. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Investig. Ophthalmol. Vis. Sci. 2003, 44, 3771–3777.
22. Klein, R.; Klein, B.E.; Marino, E.K.; Kuller, L.H.; Furberg, C.; Burke, G.L.; Hubbard, L.D.Early age-related maculopathy in the cardiovascular health study. Ophthalmology2003, 110, 25–33.
23. Tan, J.S.; Mitchell, P.; Smith, W.; Wang, J.J. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: The Blue Mountains Eye study. Ophthalmology 2007, 114, 1143–1150.
24. Eye-Disease-Case-Control-Study-Group. Risk factors for neovascular age-related macular degeneration. Arch. Ophthalmol. 1992, 110, 1701–1708.
25. Klein, R.; Klein, B.E.; Franke, T. The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The beaver dam eye study. Ophthalmology1993, 100, 406–414.
26. Vinding, T. Age-related macular degeneration. An epidemiological study of 1000 elderly individuals. With reference to prevalence, funduscopic findings, visual impairment and risk factors. Acta Ophthalmol. Scand. Suppl. 1995, 217, 1–32.
27. Klein, R.; Cruickshanks, K.J.; Myers, C.E.; Sivakumaran, T.A.; Iyengar, S.K.; Meuer, S.M.; Schubert, C.R.; Gangnon, R.E.; Klein, B.E. The relationship of atherosclerosis to the 10-year cumulative incidence of age-related macular degeneration: The beaver dam studies. Ophthalmology2013, 120, 1012–1019.
28. Klein, R.; Knudtson, M.D.; Klein, B.E. Statin use and the five-year incidence and progression of age-related macular degeneration. Am. J. Ophthalmol. 2007, 144, 1–6.
29. Hogg, R.E.; Woddside, J.V.; Gilchrist, S.E.; Graydon, R.; Fletcher, A.E.; Chan, W.; Knox, A.; Cartmill, B.; Chakravarthy, U. Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology2008, 115, 1046–1052.
30. Klein, R.; Deng, Y.; Klein, B.E.; Hyman, L.; Seddon, J.; Frank, R.N.; Wallace, R.B.; Hendrix, S.L.; Kuppermann, B.D.; Langer, R.D.; et al. Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women’s Health Initiative Sight Exam ancillary study. Am. J. Ophthalmol. 2007, 143, 473–483.
31. Feeney-Burns, L.; Berman, E.R.; Rothman, H. Lipofuscin of human retinal pigment epithelium. Am. J. Ophthalmol. 1980, 90, 783–791.
32. Panda-Jonas, S.; Jonas, J.B.; Jakobczyk-Zmija, M. Retinal pigment epithelial cell count, distribution, and correlations in normal human eyes. Am. J. Ophthalmol. 1996, 121, 181–189.
33. Sarks, S.H. Ageing and degeneration in the macular region: A clinico-pathological study. Br. J. Ophthalmol. 1976, 60, 324–341.
34. Sarks, S.; Cherepanoff, S.; Killingsworth, M.; Sarks, J. Relationship of basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2007, 48, 968–977.
35. Klein, M.L.; Ferris, F.L., III; Armstrong, J.; Hwang, T.S.; Chew, E.Y.; Bressler, S.B.; Chandra, S.R. Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology2008, 115, 1026–1031.
36. Schmitz-Valckenberg, S.; Bindewald-Wittich, A.; Dolar-Szczasny, J.; Dreyhaupt, J.; Wolf, S.; Scholl, H.P.; Holz, F.G. Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with amd. Investig. Ophthalmol. Vis. Sci. 2006, 47, 2648–2654.
37. Holz, F.G.; Bellman, C.; Staudt, S.; Schutt, F.; Volcker, H.E. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2001, 42, 1051–1056.
38. AREDS-Study-Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: Areds report no. 8. Arch. Ophthalmol. 2001, 119, 1417–1436.
39. Newsome, D.A.; Swartz, M.; Leone, N.C.; Elston, R.C.; Miller, E. Oral zinc in macular degeneration. Arch. Ophthalmol. 1988, 106, 192–198.
40. Cho, E.; Stampfer, M.J.; Seddon, J.M.; Hung, S.; Spiegelman, D.; Rimm, E.B.; Willett, W.C.; Hankinson, S.E. Prospective study of zinc intake and the risk of age-related macular degeneration. Ann. Epidemiol. 2001, 11, 328–336.
41. Smith, W.; Mitchell, P.; Rochester, C. Serum beta carotene, alpha tocopherol, and age-related maculopathy: The blue mountains eye study. Am. J. Ophthalmol. 1997, 124, 838–840.
42. VandenLangenberg, G.M.; Mares-Perlman, J.A.; Klein, R.; Klein, B.E.; Brady, W.E.; Palta, M. Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the beaver dam eye study. Am. J. Epidemiol. 1998, 148, 204–214.
43. Mares-Perlman, J.A.; Fisher, A.I.; Klein, R.; Palta, M.; Block, G.; Millen, A.E.; Wright, J.D. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. Am. J. Epidemiol. 2001, 153, 424–432.
44. Taylor, H.R.; Tikellis, G.; Robman, L.D.; McCarty, C.A.; McNeil, J.J. Vitamin E supplementation and macular degeneration: Randomised controlled trial. BMJ 2002, 325, doi:10.1136/bmj.325.7354.11.
45. AREDS2-Study-Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The age-related eye disease study 2 (AREDS2) randomized clinical trial. JAMA2013, 309, 2005–2015.
46. Regillo, C.D. Lampalizumab (anti-factor D) in patients with geography atrophy: The mahalo phase 2 results. In proceedings of the 2013 Annual Meeting of the American Academy of Ophthalmology, 16–19 November 2013, New Orleans, LA, USA.
47. Tarallo, V.H.Y.; Gelfand, B.D.; Dridi, S.; Kerur, N.; Kim, Y.; Cho, W.G.; Kaneko, H.; Fowler, B.J.; Bogdanovich, S.; Albuquerque, R.J.; et al. Dicer1 loss and alu rna induce agerelated macular degeneration via the NLRP3 inflammasome and MYD88. Cell 2012, 149, 847– 859.
48. Kubota, R.; Boman, N.L.; David, R.; Mallikaarjun, S.; Patil, S.; Birch, D. Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina2012, 32, 183–188.
49. Mata, N.L.; Lichter, J.B.; Vogel, R.; Han, Y.; Bui, T.V.; Singerman, L.J. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina2013, 33, 498–507.
50. Trichonas, G.; Murakami, Y.; Thanos, A.; Morizane, Y.; Kayama, M.; Debouck, C.M.; Hisatomi, T.; Miller, J.W.; Vavvas, D.G. Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis. Proc. Natl. Acad. Sci. USA2010, 107, 21695–21700.
51. Tsai, J.C. Canadian journal of ophthalmology lecture: Translational research advances in glaucoma neuroprotection. Can. J. Ophthalmol. 2013, 48, 141–145.
52. Wong, W.T.; Kam, W.; Cunningham, D.; Harrington, M.; Hammel, K.; Meyerle, C.B.; Cukras, C.; Chew, E.Y.; Sadda, S.R.; Ferris, F.L. Treatment of geographic atrophy by the topical administration of OT-551: Results of a phase II clinical trial. Investig. Ophthalmol. Vis. Sci. 2010, 51, 6131–6139.
53. Zhang, K.; Hopkins, J.J.; Heier, J.S.; Birch, D.G.; Halperin, L.S.; Albini, T.A.; Brown, D.M.; Jaffe, G.J.; Tao, W.; Williams, G.A. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc. Natl. Acad. Sci. USA2011, 108, 6241–6245.
54. Schwartz, S.D.; Hubschman, J.P.; Heilwell, G.; Franco-Cardenas, V.; Pan, C.K.; Ostrick, R.M.; Mickunas, E.; Gay, R.; Klimanskaya, I.; Lanza, R. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet2012, 379, 713–720.
55. Schwartz, S.D.; Regillo, C.D.; Lam, B.L.; Elliot, D.; Rosenfeld, P.J.; Gregori, N.Z.; Hubschman, J.P.; Davis, J.L.; Heilwell, G.; Spirn, M; et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: Follow-up of two open-label phase 1/2 studies. Lancet2014, 15, doi:10.1016/S0140-6736(14)61376-3.
56. MPS-Study-Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch. Ophthalmol. 1982, 100, 912–918.
57. MPS-Study-Group. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Arch. Ophthalmol. 1986, 104, 694–701.
58. MPS-Study-Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch. Ophthalmol. 1994, 112, 500–509.
59. MPS-Study-Group. The influence of treatment extent on the visual acuity of eyes treated with krypton laser for juxtafoveal choroidal neovascularization. Arch. Ophthalmol. 1995, 113, 190–194.
60. MPS-Study-Group. Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Arch. Ophthalmol. 1994, 112, 489–499.
61. MPS-Study-Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch. Ophthalmol. 1993, 111, 1200–1209.
62. TAP-Study-Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials—Tap report. Arch. Ophthalmol. 1999, 117, 1329–1345.
63. Bressler, N.M. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-tap report 2. Arch. Ophthalmol. 2001, 119, 198–207.
64. Blumenkranz, M.S.; Bressler, N.M.; Bressler, S.B.; Donati, G.; Fish, G.E.; Haynes, L.A.; Lewis, H.; Miller, J.W.; Mones, J.M.; Potter, M.J.; et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: Three-year results of an open-label extension of 2 randomized clinical trials—Tap report no. 5. Arch. Ophthalmol. 2002, 120, 1307–1314.
65. Gragoudas, E.S.; Adamis, A.P.; Cunningham, E.T., Jr.; Feinsod, M.; Guyer, D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 2004, 351, 2805–2816.
66. Brown, D.M.; Michels, M.; Kaiser, P.K.; Heier, J.S.; Sy, J.P.; Ianchulev, T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009, 116, doi:10.1016/j.ophtha.2008.10.018.
67. Rosenfeld, P.J.; Brown, D.M.; Heier, J.S.; Boyer, D.S.; Kaiser, P.K.; Chung, C.Y.; Kim, R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355, 1419–1431.
68. Martin, D.F.; Maguire, M.G.; Fine, S.L.; Ying, G.S.; Jaffe, G.J.; Grunwald, J.E.; Toth, C.; Redford, M.; Ferris, F.L., III. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology2012, 119, 1388–1398.
69. Martin, D.F.; Maguire, M.G.; Ying, G.S.; Grunwald, J.E.; Fine, S.L.; Jaffe, G.J. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2011, 364, 1897–1908.
70. Browning, D.J.; Kaiser, P.K.; Rosenfeld, P.J.; Stewart, M.W. Aflibercept for age-related macular degeneration: A game-changer or quiet addition? Am. J. Ophthalmol. 2012, 154, 222–226.
71. Stewart, M.W. Aflibercept (VEGF trap-eye): The newest anti-VEGF drug. Br. J. Ophthalmol. 2012, 96, 1157–1158.
72. Papadopoulos, N.; Martin, J.; Ruan, Q.; Rafique, A.; Rosconi, M.P.; Shi, E.; Pyles, E.A.; Yancopoulos, G.D.; Stahl, N.; Wiegand, S.J. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis2012, 15, 171–185.
73. Heir, J.S.; Brown, D.M.; Chong, V.; Korobelnik, J.-F.; Kaiser, P.K.; Nguyen, Q.D.; Kirchhof, B.; Ho, A.; Ogura, Y.; Yancopoulos, G.D.; et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology2012, 119, 2537–2548.
74. Dugel, P.U. A phase 2b study of e10030, a platelet derived growth factor (PDGF) inhibitor in combination with a vascular endothelial growth factor (VEGF) inhibitor for neovascular age-related macular degeneration (AMD). In proceedings of the 36th Annual Meeting of the Macula Society, Dana Point, CA, USA, 2013.
75. Yonekawa, Y.; Andreoli, C.; Miller, J.B.; Loewenstein, J.I.; Sobrin, L.; Eliott, D.; Vavvas, D.G.; Miller, J.W.; Kim, I.K. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am. J. Ophthalmol.2013, 156, doi:10.1016/j.ajo.2013.03.030.
76. Bakall, B.; Folk, J.C.; Boldt, H.C.; Sohn, E.H.; Stone, E.M.; Russell, S.R.; Mahajan, V.B. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am. J. Ophthalmol.2013, 156, doi:10.1016/j.ajo.2013.02.017.
77. Ho, V.Y.; Yeh, S.; Olsen, T.W.; Bergstrom, C.S.; Yan, J.; Cribbs, B.E.; Hubbard, G.B., III. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am. J. Ophthalmol.2013, 156, doi:10.1016/j.ajo.2013.02.009.
78. Cho, H.; Shah, C.P.; Weber, M.; Heier, J.S. Aflibercept for exudative amd with persistent fluid on ranibizumab and/or bevacizumab. Br. J. Ophthalmol. 2013, 97, 1032–1035.
79. Kaiser, P.K.; Boyer, D.S.; Cruess, A.F.; Slakter, J.S.; Pilz, S.; Weisberger, A. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of the denali study. Ophthalmology2012, 119, 1001–1010.
80. Larsen, M.; Schmidt-Erfurth, U.; Lanzetta, P.; Wolf, S.; Simader, C.; Tokaji, E.; Pilz, S.; Weisberger, A. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month mont blanc study results. Ophthalmology2012, 119, 992–1000.
81. Jackson, T.L.; Chakravarthy, U.; Kaiser, P.K.; Slakter, J.S.; Jan, E.; Bandello, F.; O’Shaughnessy, D.; Gertner, M.E.; Danielson, L.; Moshfeghi, D.M. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the intrepid study. Ophthalmology2013, 120, 1893–1900.
82. Moshfeghi, A.A.; Morales-Canton, V.; Quiroz-Mercado, H.; Velez-Montoya, R.; Zavala-Ayala, A.; Shusterman, E.M.; Kaiser, P.K.; Sanislo, S.R.; Gertner, M.; Moshfeghi, D.M. 16 GY low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a “radiation-first” strategy. Br. J. Ophthalmol. 2012, 96, 1320–1324.
83. Guerrero-Naranjo, J.L.; Quiroz-Mercados, H.; Sanchez-Bermudez, G.; Schoonewolff, F.; Salinas-Longoria, S.; Romero-Vera, R.; Tao, W.; Beckman, R.; Morales-Canton, V. Safety of implantation of the NT-503 device in patients with choroidal neovascularization secondary to age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2013, 54, ARVO E-abstract 3298.
84. Clinicaltrials.Gov. Phase I Dose Escalation Safety Study of Retinostat in Advanced Age-Related Macular Degeneration (AMD) (GEM). Clinicaltrials.Gov Website. Available online: http://clinicaltrials.gov/show/nct01301443 (accessed on 19 May 2014).
85. Campochiaro, P.A.; Channa, R.; Berger, B.B.; Heier, J.S.; Brown, D.M.; Fiedler, U.; Hepp, J.; Stumpp, M.T. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: A phase I/II study. Am. J. Ophthalmol. 2013, 155, 697–704.
86. Kaiser, P.K.; Symons, R.C.; Shah, S.M.; Quinlan, E.J.; Tabandeh, H.; Do, D.V.; Reisen, G.; Lockridge, J.A.; Short, B.; Guerciolini, R.; et al. Rnai-based treatment for neovascular age-related macular degeneration by sirna-027. Am. J. Ophthalmol. 2010, 150, doi:10.1016/j.ajo.2010.02.006.
87. Zhang, M.; Zhang, J.; Yan, M.; Luo, D.; Zhu, W.; Kaiser, P.K.; Yu, D.C. A phase 1 study of kh902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology2011, 118, 672–678.
88. Lpath, Inc. Overview. Lpath Incorporated Website. Available online: http://www.lpath.com/about-lpath/overview (accessed on 19 May 2014).
89. Kaiser, P.K.; Boyer D.S.; Campochiaro, P.A.; Guerro-Nranjo, J.L.; Heier, J.; Kornfield, J.; Kuppermann, B.; Quiroz-Mercado, H.; Salinas-Longoria, S.; Schwartz, S. Integrin peptide therapy: The first wet amd experience. Investig. Ophthalmol. Vis. Sci.2013, 54, ARVO E-abstract 2177.
90. Allergan. Allergan and Molecular Partners Enter into Exclusive Alliance. Allergan Website. Available online: http://agn.Client.Shareholder.Com/releasedetail.Cfm?Releaseid=701294 (accessed on 19 May 2014).
91. Ohr Pharmaceutics, Inc. Squalamine. Ohr Pharmaceuticals Website. Available online: http://www.Ohrpharmaceutical.Com/research/squalamine (accessed on 19 May 2014).
92. Grassmann, F.; Schoenberger, P.G.; Brandl, C.; Schick, T.; Hasler, D.; Meister, G.; Fleckenstein, M.; Linder, M.; Helbig, H.; Fauser, S.; et al.A circulating microRNA profile is associated with late-stage neovascular age-related macular degeneration. PLoS One 2014, 9, e107461.
93. Askou, A.L. Development of gene therapy for treatment of age-related macular degeneration. Acta Ophthalmol. 2014, 92, 1–38.
94. Yanai, R.; Mulki, L.; Hasegawa, E.; Takeuchi, K.; Sweigard, H.; Suzuki, J.; Gaissert, P.; Vavvas, D.G.; Sonoda, K.H.; Rothe, M.; et al. Cytochrome P450-generated metabolites derived from ω-3 fatty acids attenuate neovascularisation. Proc. Natl. Acad. Sci. USA2014, 111, 9603–9608.
95. Chew, E.Y.; Clemons, T.E.; Bressler, S.B.; Elman, M.J.; Danis, R.P.; Domalpally, A.; Heier, J.S.; Kim, J.E.; Garfinkel, R. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology2014, 121, 535–544.
96. Jackson, G.R.; Scott, I.U.; Kim, I.K.; Quillen, D.A.; Iannaccone, A.; Edwards, J.G. Diagnostic sensitivity and specificity of dark adaptometry for detection of age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2014, 55, 1427–1431.